Danaher Down 22% in 2025: Does Masimo Deal Signal Buy Opportunity?
Danaher has shed 22% this year, but its Masimo acquisition may signal a strategic turning point for patient-connected diagnostics.
Danaher Corporation has dropped 22% in 2025, raising urgent questions about whether the life sciences giant's deal to acquire Masimo Corporation marks a bottom — or a deeper slide. The stock's steep decline has put the company squarely in the crosshairs of value-oriented investors debating whether the sell-off has gone too far.
The Masimo acquisition represents a fundamental strategic pivot for Danaher's diagnostics segment. Rather than continuing to anchor its business in conventional laboratory testing, the company is steering toward patient-connected devices that deliver real-time data streams — a corner of healthcare technology that commands premium growth valuations and is attracting considerable industry attention.
Read more Cantor Equity Partners Delays Shareholder Vote to July 2 →
The move reflects a broader industry trend: health systems and clinical networks are increasingly demanding continuous, bedside monitoring rather than point-in-time lab results. By absorbing Masimo's capabilities, Danaher would gain direct access to that faster-growing market segment, potentially repositioning its diagnostics unit as a higher-margin, recurring-revenue business rather than a cyclical equipment play.
For investors, the central question is one of timing and conviction. A 22% drawdown can be either a value trap or a genuine entry point, and the answer often hinges on execution risk tied to large acquisitions. Integration costs, regulatory considerations, and the pace at which Danaher can scale Masimo's connected-monitoring technology will all shape how quickly — if at all — the thesis plays out.
Analysts and shareholders will be closely watching Danaher's next earnings disclosures for clarity on deal economics and updated segment guidance. Continue reading at Yahoo.
